Company profile
Vega Therapeutics
Providing solutions for patients with rare blood disorders, starting with VWD
- Industry
- Biotechnology
- Employees
- 2
Vega Therapeutics company summary
Vega Therapeutics is a company in the Biotechnology industry. On LinkedIn the company has around 2 employees.
What technology does Vega Therapeutics use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Vega Therapeutics
VGA039 is a monoclonal antibody therapy with a novel mechanism of action that regulates Protein S, a key component in bringing balance to the blood clotting process. VGA039 has the potential to be a universal hemostatic therapy that can treat numerous bleeding disorders, starting with von Willebrand disease (VWD). As a subcutaneously self-administered antibody therapy with convenient dosing, VGA039 has the potential to significantly reduce the treatment burden for patients.
Compare companies similar to Vega Therapeutics
More companies in Biotechnology.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Vega Therapeutics vega-therapeutics.com | Biotechnology | 2 | - | - |
 Regeneron regeneron.com | Biotechnology | 17,234 | - | Tarrytown, New York |
 Bharat Biotech bharatbiotech.com | Biotechnology | 2,035 | 1996 | Hyderabad, Telangana |
 Enzene Biosciences Ltd enzene.com | Biotechnology | 1,023 | 2008 | Pune, Maharashtra |
| Biotechnology | 393 | - | Bethesda, MD | |
 LifeCell International Pvt.Ltd lifecell.in | Biotechnology | 2,650 | 2004 | Chennai, India |
 TMG - Tropical Melhoramento & Genética tmg.agr.br | Biotechnology | 692 | 2001 | Cambé, PR |
 Organica Biotech organicabiotech.com | Biotechnology | 146 | 2000 | Mumbai, Maharashtra |
 Allogene Therapeutics allogene.com | Biotechnology | 217 | 2017 | South San Francisco, California |
 Labtest Diagnóstica S.A. labtest.com.br | Biotechnology | 227 | 1971 | Lagoa Santa, Minas Gerais |
 Orchard Therapeutics - U.S. orchard-tx.com | Biotechnology | 243 | 2015 | London, United Kingdom |
Frequently asked questions about Vega Therapeutics
What does Vega Therapeutics do?
VGA039 is a monoclonal antibody therapy with a novel mechanism of action that regulates Protein S, a key component in bringing balance to the blood clotting process. VGA039 has the potential to be a universal hemostatic therapy that can treat numerous bleeding disorders, starting with von Willebrand disease (VWD). As a subcutaneously self-administered antibody therapy with convenient dosing, VGA039 has the potential to significantly reduce the treatment burden for patients.
How many employees does Vega Therapeutics have?
Vega Therapeutics has around 2 employees on LinkedIn.
Build a lead list from companies like Vega Therapeutics
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.